Table 1.

Patient demographics and baseline disease characteristics

CLL (n = 10)Lymphoma (n = 15)
Age, years, median (range)64 (57–80)66 (28–83)
Sex, male, n (%)5 (50.0)6 (40.0)
ECOG PS, n (%)
 03 (30.0)3 (20.0)
 17 (70.0)11 (73.3)
 201 (6.7)
Disease type/subtypea, n (%)
 CLL10 (100)b
 Lymphoma15 (100)
  DLBCL4 (26.7)
  FL, grades 1–23 (20.0)
  FL, grade 31 (6.7)
  Hodgkin lymphoma2 (13.3)
  Lymphoplasmacytic lymphoma3 (20.0)
  Transformed lymphoma2 (13.3)
Disease status, n (%)c
 Refractory4 (40.0)7 (46.7)
 Relapsed6 (60.0)8 (53.3)
Bulky disease, n (%)d8 (80.0)4 (26.7)
Prior radiation treatments, n (%)2 (20)4 (26.7)
Prior anticancer regimens within 5 years prior to screening, median (range)1.0 (1.0–7.0)3.0 (0–9.0)

Abbreviation: FL, follicular lymphoma.

  • aDiagnosis at baseline.

  • bSix of 10 patients with CLL were from del17p or del11q high-risk prognostic subgroups; 5 of 8 evaluated patients had unmutated IGHV.

  • cDue to the absence of a clear definition of refractory in the protocol, relapsed versus refractory status for lymphoma patients was derived subsequently by two independent observers based on prior treatment data. Refractory was defined as a less than 6 month duration since the most recent prior therapy.

  • dBulky disease was recorded as determined by investigator.